Clinical Trials
21 trialsNCT04971226 2026-06-05
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
NCT03654768 2025-12-18
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT03106779 2025-04-08
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Novartis
Phase 3 Completed
NCT04793399 2024-03-19
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica
Phase 1/2 Terminated
NCT02311998 2023-07-17
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02269267 2023-03-03
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Medical College of Wisconsin
Phase 2 Completed
NCT01903733 2022-07-19
Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Pfizer
Phase NA Completed
NCT04006847 2022-07-01
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT03128411 2022-05-19
Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 2 Completed
NCT02228382 2021-12-30
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Pfizer
Phase 4 Terminated
NCT00880009 2021-09-27
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer
Pfizer
Phase 2 Terminated
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT02906696 2020-05-11
Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00574873 2019-01-08
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Pfizer
Phase 3 Completed
NCT00261846 2017-07-27
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
Pfizer
Phase 2 Completed
NCT01331291 2016-07-25
Bosutinib in Adult Patients With Recurrent Glioblastoma
Massachusetts General Hospital
Phase 2 Completed
NCT00811070 2016-06-28
Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias
Pfizer
Phase 2 Completed
NCT00959946 2013-02-22
Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
Pfizer
Phase 1/2 Terminated
NCT00195260 2013-02-11
Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
Pfizer
Phase 1 Completed
NCT00319254 2013-01-31
Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
Pfizer
Phase 2 Completed
NCT00793546 2012-11-05
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer
Pfizer
Phase 2 Terminated